Evaluating Breath Methane as a Diagnostic Test for Constipation-Predominant IBS
- 18 March 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 55 (2), 398-403
- https://doi.org/10.1007/s10620-009-0778-4
Abstract
Studies suggest that subjects with IBS have altered gut flora. Among these findings, methane production is more commonly associated with constipation-predominant symptoms. In this study, we prospectively evaluated the role of methane as a diagnostic test. Consecutive Rome I positive IBS patients referred for a lactulose breath test were eligible to participate. After exclusion criteria, subjects completed a symptom questionnaire grading bloating, diarrhea, and constipation on a VAS scale (0–100 mm). Once completed, a physician interviewed the subjects and rated the subject accordingly, and also determined whether the patient had C-IBS, D-IBS, or neither. Subjects and physicians were blinded to the results of the breath test. The presence of methane in the breath test was compared to the results of the scoring by subjects and physicians. A total of 56 Rome I positive IBS subjects were enrolled. During breath testing, 28 subjects produced methane. Good agreement between physician’s evaluation and the patient’s was seen (diarrhea = 0.69; constipation = 0.69; bloating = 0.62). The severity of constipation was noted to be greater in the methane group (49.3 ± 28.7) than in the non-methane group (25.3 ± 31.47) (P < 0.01). In contrast, diarrhea was less severe in the methane group (12.3 ± 21.0) than the non-methane group (36.7 ± 32.4) (P < 0.01). Out of the 56 patients, 23 C-IBS subjects were identified by the physician. When methane was used to predict the assignment of C-IBS compared to non-C-IBS, it had a sensitivity of 91.7% and a specificity of 81.3% (OR = 47.7, CI = 9.4–232, P < 0.00001). In conclusion, methane is a potential diagnostic test for the identification of C-IBS and may guide treatment.Keywords
This publication has 30 references indexed in Scilit:
- Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distressNeurogastroenterology & Motility, 2008
- T1390 Rifaximin for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained ResponseGastroenterology, 2008
- A Systematic Review of Diagnostic Tests for Small Intestinal Bacterial OvergrowthDigestive Diseases and Sciences, 2007
- Small intestinal bacterial overgrowth in patients with irritable bowel syndromeGut, 2007
- Neomycin Improves Constipation-Predominant Irritable Bowel Syndrome in a Fashion That Is Dependent on the Presence of Methane Gas: Subanalysis of a Double-Blind Randomized Controlled StudyDigestive Diseases and Sciences, 2006
- Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case–control study in irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2005
- Efficacy of Current Drug Therapies in Irritable Bowel Syndrome: What Works and Does Not WorkGastroenterology Clinics of North America, 2005
- Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowthAlimentary Pharmacology & Therapeutics, 2005
- The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjectsAlimentary Pharmacology & Therapeutics, 2003
- Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonistAlimentary Pharmacology & Therapeutics, 1999